RFA-MH-26-120: BRAIN Initiative Reagent Resources for Brain Cell Type-Specific Access (U24)

RFA-MH-26-120: BRAIN Initiative Reagent Resources for Brain Cell Type-Specific Access (U24)

This NIH opportunity is a BRAIN Initiative cooperative agreement built around a very specific kind of infrastructure work: establishing facilities that can produce and distribute brain cell type-specific access and manipulation reagents at scale. The public listing makes clear that the award is intended to help minority-serving institutions and IDeA-eligible institutions become reliable resource hubs for neuroscience, not just places that host a one-off experiment.

That distinction matters. This is not a conventional hypothesis-driven R01. It is a resource-production and distribution call with a community-facing purpose, which means the strongest applications will read like a combination of technical plan, operations manual, and collaboration strategy.

Key details at a glance

The listing also notes that the opportunity is tied to Assistance Listing 93.242 and other NIH research categories, which is a useful reminder that the work sits at the intersection of neuroscience, biomedical infrastructure, and translational research support.

What this opportunity is actually funding

The core purpose is straightforward: NIH wants awardees who can build facilities capable of producing and distributing reagents that give researchers selective access to brain cell types. The public synopsis says those reagents may include viral vectors, nucleic acid constructs, and nanoparticles. The goal is to help the neuroscience community use those tools broadly and reliably across vertebrate species and related research settings.

That makes this call different from a standard tool-development grant. The emphasis is not just on inventing a reagent. It is on taking a promising reagent from a pilot project and turning it into something that can be manufactured, quality-controlled, distributed, and optimized for broader use. The successful applicant will need to think in terms of throughput, reproducibility, community demand, and support workflows.

The opportunity also implies ongoing coordination with the broader BRAIN Initiative Armamentarium effort. The page says awardees will work with other Armamentarium projects and with the neuroscience community to optimize use of the reagents. In practice, that means the award is likely to favor teams that can operate like a shared resource center, not just a single laboratory.

If you are reading this as a potential applicant, the key question is simple: can your institution or consortium turn early-stage neuroscience reagents into dependable research resources that other labs can actually use?

Who this call fits best

This opportunity is best suited to teams that already have some mix of technical production capability, biosafety awareness, distribution planning, and institutional support. It is especially relevant if your institution has a mission or track record in serving underrepresented or resource-limited research communities.

You should prioritize the call if you can say yes to several of these:

• You can build or already manage a facility that handles reagent production, QC, storage, and shipment.
• You have the staff and administrative backing to support a multi-year cooperative agreement.
• Your team can work across neuroscience, molecular biology, vector engineering, materials, or related production disciplines.
• Your institution can host a resource that serves more than one investigator and more than one project.
• You are comfortable with NIH-style compliance, documentation, and progress reporting.

The strongest conceptual fit is probably for institutions that want to become infrastructure leaders in BRAIN Initiative-enabled neuroscience. That means the award is likely to reward operational maturity as much as scientific novelty.

If your plan is mostly about a single PI’s discovery project, this is probably not the right call. If your plan is about building a durable shared resource that other neuroscientists can rely on, it may be an excellent fit.

Eligibility and institutional fit

The public listing is broader than the program’s target narrative, so applicants should read both layers carefully. On the one hand, NIH lists a wide set of eligible applicant types, including U.S. government bodies, nonprofits, educational institutions, small businesses, and some other organization types. On the other hand, the synopsis makes clear that the program is intended to support facilities at minority-serving institutions and IDeA-eligible institutions.

That combination suggests a practical interpretation:

1. You need to fit NIH’s general applicant rules.
2. You also need to fit the program’s resource-center mission.
3. The institution should be able to host a facility that serves the broader neuroscience community.

The listing also states that non-domestic entities cannot apply, while foreign components are allowed. That is an important distinction for international collaborations. A U.S. domestic applicant may be able to include foreign components, but a foreign organization should not assume it can lead the application.

Because this is a cooperative agreement, NIH involvement is not just symbolic. Applicants should expect active programmatic coordination and should plan for a relationship that includes reporting, milestone tracking, and potential collaboration with other BRAIN Initiative awardees.

How to approach the application

The public summary does not expose the full package requirements, so the safest approach is to treat this as an NIH infrastructure submission and prepare the standard building blocks early.

At minimum, your draft should probably cover:

• the scientific and technical rationale for the reagents you plan to produce,
• the source or pilot basis for the reagents,
• production workflow and scale-up logic,
• quality control and release criteria,
• distribution model and user support,
• governance, staffing, and sustainability,
• and the plan for collaboration with the BRAIN Initiative community.

The application should also show that the facility can do more than make material in a vacuum. Reviewers will want to know who will use the reagents, how demand will be managed, how feedback will be collected, and how the facility will improve the tools over time.

In a call like this, evidence quality matters. A strong application is likely to include concrete examples of:

• prior reagent production or technology transfer,
• experience with shipment, storage, and cold-chain management if relevant,
• user support systems,
• existing institutional biosafety or compliance processes,
• and a realistic staffing plan.

If you are assembling a consortium, make the division of labor explicit. NIH resource awards tend to read better when each participant has a clear operational role instead of a vague “collaboration” label.

Funding mechanics and timeline

One thing the public listing does not show is a dollar amount, award ceiling, or expected number of awards. That means you should not build a budget narrative around a presumed cap that is not in the public record.

What is confirmed is the schedule and the instrument:

• Posted: 2024-09-25
• Closing date: 2027-06-15
• Archive date: 2027-07-21
• Funding instrument: Cooperative agreement
• Cost sharing: No

For planning purposes, the long closing window is helpful. It suggests the opportunity is meant to stay available for a substantial period rather than forcing a short-turn submission scramble. But that does not mean you should wait. A resource-center application usually needs time for:

• institutional sign-off,
• budget alignment,
• facility planning,
• user access and distribution planning,
• and compliance review.

If you are deciding whether to pursue the 2026 cycle, the real planning question is not simply “Is it open?” It is “Can I build a credible operations model before June 2027?”

What reviewers are likely looking for

Because the award is a cooperative agreement tied to a community resource mission, reviewers will probably care about a different set of strengths than they would in a standard investigator-initiated grant.

The likely reviewer priorities are:

• technical feasibility of the production pipeline,
• quality control and reproducibility,
• usefulness to the neuroscience community,
• readiness to distribute at scale,
• institutional support and continuity,
• and the quality of the collaboration with the Armamentarium network.

A weak application here is usually one that overstates scientific ambition while underexplaining operations. A strong application is one that makes the facility look inevitable: the right institution, the right staff, the right workflow, and the right user ecosystem.

It also helps to show that your facility can produce something others actually need. The best proposals will not just say “we can make this reagent.” They will explain why this reagent solves a real access or specificity problem, why existing options are inadequate, and how the distribution model will make the resource more useful to external labs.

Common mistakes to avoid

Applicants can lose this kind of award in predictable ways.

1. Treating it like a basic research grant.
   This is a resource and infrastructure opportunity first. The operational plan is as important as the science.

2. Ignoring the target institutional mission.
   The page points to MSIs and IDeA-eligible institutions. If your application does not explain why your site is a strong fit for that mission, you may look mismatched.

3. Underbuilding the distribution story.
   A reagent that cannot be shipped, shared, or supported is not a community resource.

4. Leaving QC vague.
   Reviewers will expect a clear standard for batch consistency, release, and follow-up support.

5. Assuming the budget will be obvious.
   The public listing does not give an award amount. Your submission still has to show budget realism.

6. Missing the cooperative agreement mindset.
   A U24 is not the same as a fully independent investigator grant. Coordination and reporting should be part of the design.

7. Forgetting user feedback loops.
   If external labs are supposed to use these reagents, your plan should explain how you will collect feedback and improve the resource.

FAQ

Is this a clinical trial opportunity?

No. The listing identifies it as a U24 cooperative agreement for resource production and distribution, not a clinical trial call.

Is there a publicly confirmed amount?

No. The public listing does not show a total fund, award cap, or minimum award amount.

Who is this best for?

U.S.-based institutions that can host a reagent production and distribution facility, especially MSIs and IDeA-eligible institutions.

Can foreign organizations apply?

No. The listing says non-domestic entities cannot apply, though foreign components are allowed.

Where do I apply?

The official routing is through the NIH/Grants.gov process. The public listing links to the NIH Guide notice and the Grants.gov opportunity record.

Why does the cooperative agreement matter?

Because NIH likely expects substantive program involvement, collaboration, and milestone-driven execution rather than a hands-off award.

Official links and next steps

• NIH Guide notice: https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-120.html
• Grants.gov listing: https://www.grants.gov/search-results-detail/356530
• NIH grants information: [email protected]

Before you spend time drafting, confirm three things:

1. Your institution fits the NIH applicant rules.
2. Your team can actually run a reagent resource facility.
3. Your distribution and QC plan is credible enough for a community-facing award.

If those three pieces are in place, this opportunity can be a strong fit for a lab or institution that wants to move from one-off neuroscience method work into durable research infrastructure.